Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Mid-size biopharma companies are industry’s “stealth” players, occupying a small but important space in the race for new innovative therapies. In Vivo explores the growth prospects of one of the more prominent entrants in this space, Merck KGAA, whose fortunes depend heavily on building a strong oncology and immunology franchise in the US market.
Oncology innovation: lots of drugs, lots of trials, sometimes not enough patients. And styles of innovation depend on whether a company has a big franchise to defend or would like one. In Vivo presents current data on sales, pipelines, trials and fails. (Free article.)
At recent industry events, Novartis and Kite Pharma highlighted opportunities and addressed challenges they face as they prepare to commercialize their CAR-T therapies. A report from Datamonitor Healthcare.
Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.
The rapidly accelerating complexity of oncology drug development demands a new way of doing business. To succeed in this new landscape, biopharma companies must transform their portfolios and partnerships, and shift toward more dynamic business and operating models and decision-making processes.
Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.
With 70 clinical trials now underway on a “next generation” of more precisely targeted antibody drug conjugates, In Vivo profiles Ambrx and Sutro Biopharma, two smaller biotechs with promising technologies and powerful partners that augment their strong science with disease awareness, deep commercial networks and global geographic reach.
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Transparency is an issue that continues to pose reputational challenges for biopharma. A key flashpoint is the disclosure – under open access rules – of clinical trial data in a climate of mounting therapeutic competition. Still, some industry players are pushing the boundaries around open access. Project Data Sphere, a non-profit group backed by the CEO Roundtable on Cancer, is taking advantage of new IT platforms and the rich target potential in discovery science to press for a larger industry consensus around new ways to release high-value data embedded in years of trials, all for the benefit of cancer patients.
BTG's range of interventional oncology technologies puts it in an enviable position in R&D initiatives that require a holistic view across cancer and the best-targeted therapies. The UK-listed company will now take this to another level following an agreement with the Society of Interventional Oncology to explore the role of minimally invasive therapies in immuno-oncology.
Oncology drug development is undergoing rapid shifts. Bain research shows companies that seek to lead in speciﬁc vertical categories outperform rivals that invest across a broad spectrum of cancer targets.
ASCO’s 2017 annual meeting is expanding its focus on patient wellness beyond the clinic, with new research highlighting prevention, alternative treatments post-surgery, psycho-social factors and other issues reflecting the concerns of a growing new constituency of cancer survivors. In Vivo discusses this year’s agenda with ASCO’s CMO, Richard Schilsky.
Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.
The pursuit by the industry to find novel combinations that can address more patients and more tumor types has driven overall immuno-oncology deal activity by big pharma and mid pharma companies between 2012 and 2016.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.
Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.
The US Medicare agency issued on 12 January its final MCIT rule allowing instant reimbursement for FDA breakthrough devices – unless the incoming Biden administration blocks it.
Outgoing US FDA chief Stephen Hahn has signaled that he’ll seek a posting in public health, where he can increase equity and help in the fight against COVID-19.
Radiologists, Other Out-Of-Network Providers See Partial Win In ‘Surprise Billing’ Law, Attorney Says
The US Congress’ choice to use an arbitration model will make a new “surprise billing” law easier to swallow, a corporate attorney tells Medtech Insight.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.